Rimini
Sunday, February 13, 2011
Thursday, February 10, 2011
Why Are Peop[le Posting Numbers In Their Statuses
With GattoMur's prophetic
The final scene de Nanni Moretti's The Caiman
Nothing's final, "Caiman" by Nanni Moretti on Rai3 tonight. On the day that the Milan prosecutors asked the court to immediately report to the Prime Minister in case Ruby, "Talk to me," the program hosted by Serena Dandini in the late evening, had to offer the latest sequence of the film, which is dedicated to the process to Berlusconi, played by the director himself. But in the evening I received a letter from the Deputy Director General, Antonio Marano, who wanted to cut the scene from seven to three minutes, otherwise the devaluation of the product and thus no transmissions in the future on any network Rai: a cut in the which Moretti, who had given his consent to the broadcast of the last part of the film, was opposed. Hence the decision of the management of RAI-3, in agreement with the director but also with the Dandini and the team of the program, not to send more in the last minute wave of "Caiman" ;.
Tuesday, February 8, 2011
What Do I Write On My Boss's Birthday Card
change from the nerve center of anti-cancer molecule by three million € The plan
From Corriere della Sera on Tuesday, February 8:
Research Institute The rebirth after the crash thanks to investments of the region and Unicredit. Here the road was opened to chemotherapy
LONDON - Since the discovery dell'adriamicina (considered the forerunner of the chemotherapy drug in the world), the financial collapse, until the Renaissance. In 46 years, the parable of the Center Nerviano, near Milan, may symbolize the dramatic Italian scientific research.
It is these days the news of the sale of a molecule to the multinational anti-cancer Genentech (Roche), among the leading companies in the biotech market. "A shot that does it again shine pharmaceutical research against cancer," assures Sergio Dompé, President of Farmindustria. And to think that not even two years ago to save the nerve center, with its 170 workers and 530 researchers, scientists had to take the field such as Umberto Veronesi, Gianni Bonadonna, Silvio Garattini and Alberto Mantovani. The year was 1965 when the company built a half hour from Farmitalia Milan what is destined to become the first private research center in Italy for cancer. These were the boom years of pharmaceutical companies and discoveries that begin to revolutionize cancer treatment: and here - with the merger between the eighties and Farmitalia Carlo Erba-Montedison - it tells the story of a great brand of Italian industry, and the first pharmaceutical manufacturer of the time. Come, then, the foreign and, in 1992, with Sweden's Pharmacia, Nerviano becomes a worldwide reference. But in 2003, under a hail of trades between corporations - with Pfizer to acquire Pharmacia - threatens to shatter the glorious past of Nerviano: the American giant decided to focus cancer research in the United States and to close the Center. It is only the first act in a crisis that threatens to wipe out the 240 research laboratories. Log on international competition, the Congregation of children of the Immaculate Conception, a nonprofit organization of pontifical right. In subsequent years, however, financial problems continue to plague the survival of Nerviano. Always on the verge of collapse. Until April 2009 when, with the closure now one step away, it triggers the mobilization of science to make it clear that "the case of nerves is a private property and that the scientific and technological expertise accumulated in the center have a value from not clear for a budget crisis. "
But the accounts are in red and the national press. It is the most difficult time for Nerviano, which is passed also and especially with the intervention of the governor of the Lombardy Region, Roberto Formigoni, nicknamed by the mass media for its interest in the Research Centre of the "white knight" of biotech Lombard. The ad that makes you breathe a sigh of relief to close last Christmas: "Regione Lombardia Nerviano bought by the Congregation of the Immaculate Conception of the children - said Formigoni -. We have signed a deal with UniCredit: Bank continues to be exposed from a financial standpoint, we commit ourselves to get directly to a balanced budget. "And now the sale of anticancer molecule to € 3 million (and subsequent royalties on the drugs sold ). Alberto explains Sciumè, since 2009 President of Nerviano, "we give rights to Genentech an exclusive license to develop a series of inhibitors with target property of the Centre for the time covered by trade secret. " It's the end of the tunnel awaited by all.
Same topic also talks about the portal Innov'azione:
Read the article 
From Corriere della Sera on Tuesday, February 8:
Research Institute The rebirth after the crash thanks to investments of the region and Unicredit. Here the road was opened to chemotherapy
LONDON - Since the discovery dell'adriamicina (considered the forerunner of the chemotherapy drug in the world), the financial collapse, until the Renaissance. In 46 years, the parable of the Center Nerviano, near Milan, may symbolize the dramatic Italian scientific research.
It is these days the news of the sale of a molecule to the multinational anti-cancer Genentech (Roche), among the leading companies in the biotech market. "A shot that does it again shine pharmaceutical research against cancer," assures Sergio Dompé, President of Farmindustria. And to think that not even two years ago to save the nerve center, with its 170 workers and 530 researchers, scientists had to take the field such as Umberto Veronesi, Gianni Bonadonna, Silvio Garattini and Alberto Mantovani. The year was 1965 when the company built a half hour from Farmitalia Milan what is destined to become the first private research center in Italy for cancer. These were the boom years of pharmaceutical companies and discoveries that begin to revolutionize cancer treatment: and here - with the merger between the eighties and Farmitalia Carlo Erba-Montedison - it tells the story of a great brand of Italian industry, and the first pharmaceutical manufacturer of the time. Come, then, the foreign and, in 1992, with Sweden's Pharmacia, Nerviano becomes a worldwide reference. But in 2003, under a hail of trades between corporations - with Pfizer to acquire Pharmacia - threatens to shatter the glorious past of Nerviano: the American giant decided to focus cancer research in the United States and to close the Center. It is only the first act in a crisis that threatens to wipe out the 240 research laboratories. Log on international competition, the Congregation of children of the Immaculate Conception, a nonprofit organization of pontifical right. In subsequent years, however, financial problems continue to plague the survival of Nerviano. Always on the verge of collapse. Until April 2009 when, with the closure now one step away, it triggers the mobilization of science to make it clear that "the case of nerves is a private property and that the scientific and technological expertise accumulated in the center have a value from not clear for a budget crisis. "
But the accounts are in red and the national press. It is the most difficult time for Nerviano, which is passed also and especially with the intervention of the governor of the Lombardy Region, Roberto Formigoni, nicknamed by the mass media for its interest in the Research Centre of the "white knight" of biotech Lombard. The ad that makes you breathe a sigh of relief to close last Christmas: "Regione Lombardia Nerviano bought by the Congregation of the Immaculate Conception of the children - said Formigoni -. We have signed a deal with UniCredit: Bank continues to be exposed from a financial standpoint, we commit ourselves to get directly to a balanced budget. "And now the sale of anticancer molecule to € 3 million (and subsequent royalties on the drugs sold ). Alberto explains Sciumè, since 2009 President of Nerviano, "we give rights to Genentech an exclusive license to develop a series of inhibitors with target property of the Centre for the time covered by trade secret. " It's the end of the tunnel awaited by all.
Same topic also talks about the portal Innov'azione:
Read the article
Subscribe to:
Posts (Atom)